United Therapeutics Corp (NASDAQ:UTHR) Chairperson and CEO Martine A. Rothblatt has executed a series of transactions involving company equity totaling several million dollars. On April 22, 2026, Ms. Rothblatt sold 9,500 shares of United Therapeutics common stock, resulting in total proceeds of $5,477,366. The sale was conducted at weighted average prices that fluctuated between $572.4767 and $580.0569 per share.
These sales were performed in conjunction with the exercise of stock options to acquire an identical amount of common stock. Through this option exercise, Ms. Rothblatt acquired 9,500 shares at a set price of $146.03 per share, representing a total acquisition cost of $1,387,285.
The transactions were carried out according to a pre-arranged Rule 10b5-1 trading plan. This specific regulatory framework was originally adopted by Ms. Rothblatt on November 7, 2025. The current plan is scheduled to remain in effect until the earlier of two dates: December 31, 2026, or the completion of exercising 1,734,410 stock options, which are set to expire on March 17, 2027.
Following these recent movements, Ms. Rothblatt maintains a direct holding of 40,513 shares of United Therapeutics common stock. Furthermore, she holds indirect ownership of 639,284 shares through various family trusts and holdings via her spouse.
The timing of this insider activity coincides with a period of high valuation for UTHR. The stock is currently trading at $572.88, which is close to its 52-week high of $607.89. This follows a substantial one-year upward trajectory where the stock gained 95.7%. While fundamental indicators remain strong - including a gross profit margin of 87.92% and a balance sheet that holds more cash than debt - some analyses suggest the stock may be slightly overvalued compared to its estimated Fair Value.
Operational and Clinical Developments
Beyond insider transactions, United Therapeutics is advancing through several clinical and research milestones. The company is preparing for 11 data presentations at the 46th Annual Meeting of the International Society for Heart and Lung Transplantation. These presentations include interim analyses from ongoing studies that indicate progress in treating pulmonary arterial hypertension and pulmonary hypertension.
In the field of regenerative medicine, the company's investigational liver assist device, miroliverELAP, has been granted the Regenerative Medicine Advanced Therapy designation by the FDA, which is intended to assist in addressing acute liver failure.
Analyst Perspectives and Market Outlook
Financial institutions have recently updated their outlooks for United Therapeutics based on clinical progress. Raymond James initiated coverage with an Outperform rating and a price target of $700, noting the potential for Tyvaso to reach peak sales exceeding $5 billion in the idiopathic pulmonary fibrosis market. H.C. Wainwright also raised its price target to $660, citing the strength of data from the TETON-1 trial. Additionally, BofA Securities increased its target to $626, following positive Phase 3 TETON-1 trial results which support the efficacy of Tyvaso for treating idiopathic pulmonary fibrosis.